Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: Results of a large, prospective study

Journal of Viral Hepatitis

Volumn 20, Issue 4, 2013, Pages

  Piluso, A ^a,b   Giannini, C ^a,b   Fognani, E ^a,b   Gragnani, L ^a,b   Caini, P ^a,b   Monti, M ^a,b   Petrarca, A ^a,b   Ranieri, J ^a,b   Urraro, T ^a,b   Triboli, E ^a,b   Laffi, G ^a,b   Zignego, A L ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Istituto Toscano Tumori ITT   (Italy)

Author keywords

hepatitis C virus; interferon based antiviral treatment; interleukin 28B; mixed cryoglobulinemia

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 28B;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CRYOGLOBULINEMIA; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRAL CLEARANCE;

ADULT; AGED; CRYOGLOBULINEMIA; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 84875214884     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12017     Document Type: Article

References (67)

1. Zignego AL, Macchia D, Monti M, et al,. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol 1992; 15: 382-386.
2. Zignego AL, Giannini C, Monti M, et al,. Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig Liver Dis 2007; 39 (Suppl 1): S38-45.
3. Ferri C, Marzo E, Longombardo G, et al,. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81: 1132-1136.
4. Ferri C, Monti M, La Civita L, et al,. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993; 82: 3701-3704.
5. Ferri C, Caracciolo F, Zignego AL, et al,. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol 1994; 88: 392-394.
6. Ferri C, La Civita L, Caracciolo F, et al,. Non-Hodgkin's lymphoma: possible role of hepatitis C virus [letter]. JAMA 1994; 272: 355-356.
7. Ferri C, La Civita L, Monti M, et al,. Can type C hepatitis infection be complicated by malignant lymphoma? [letter; comment]. Lancet 1995; 346: 1426-1427.
8. La Civita L, Zignego AL, Monti M, et al,. Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthritis Rheum 1995; 38: 1859-1860.
9. Zignego AL, Ferri C, Monti M, et al,. Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. Clin Exp Rheumatol 1995; 13 S33-37.
10. Zignego AL, Ferri C, Giannini C, et al,. Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med 1996; 124: 31-34.
11. Ferri C, La Civita L, Zignego AL, et al,. Hepatitis-C-virus infection and cancer [letter]. Int J Cancer 1997; 71: 1113-1115.
12. Ferri C, Lo Jacono F, Monti M, et al,. Lymphotropic virus infection of peripheral blood mononuclear cells in B- cell non-Hodgkin's lymphoma. Acta Haematol 1997; 98: 89-94.
13. Zignego AL, Ferri C, Giannini C, et al,. Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non- Hodgkin's lymphoma: evidence for a pathogenetic role. Arch Virol 1997; 142: 545-555.
14. Zignego AL, Ferri C, Innocenti F, et al,. Lack of preferential localization of tumoral mass in B-cell non- Hodgkin's lymphoma associated with hepatitis C virus infection [letter]. Blood 1997; 89: 3066-3068.
15. Ferri C, Longombardo G, La Civita L, et al,. Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease. J Intern Med 1994; 236: 31-36.
16. Ferri C, Zignego AL, Bombardieri S, et al,. Etiopathogenetic role of hepatitis C virus in mixed cryoglobulinemia, chronic liver diseases and lymphomas. Clin Exp Rheumatol 1995; 13 (Suppl 13): S135-140.
17. Sansonno D, De Vita S, Iacobelli AR, et al,. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998; 160: 3594-3601.
18. Zignego AL, Ferri C, Pileri SA, et al,. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007; 39: 2-17.
19. Craxi A, Laffi G, Zignego AL,. Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med 2008; 29: 85-95.
20. Zignego AL, Giannini C, Ferri C,. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol 2007; 13: 2467-2478.
21. Ferri C, Greco F, Longombardo G, et al,. Hepatitis C virus antibodies in mixed cryoglobulinemia. Clin Exp Rheumatol 1991; 9: 95-96.
22. Agnello V, Chung RT, Kaplan LM,. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-1495.
23. Ferri C, Zignego AL, Giuggioli D, et al,. HCV and cryoglobulinemic vasculitis. Cleve Clin J Med 2002; 69 (Suppl 2): SII20-23.
24. Pietrogrande M, De Vita S, Zignego AL, et al,. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011; 10: 444-454.
25. Marcellin P, Descamps V, Martinot-Peignoux M, et al,. Cryoglobulinemia with vasculitis associated with hepatitis C virus infection. Gastroenterology 1993; 104: 272-277.
26. Zignego AL, Craxi A,. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis 2008; 12: 611-636, ix.
27. EASL commission on the HCV treatment. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
28. Ghany MG, Strader DB, Thomas DL, et al,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
29. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
30. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
31. Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
32. Thomas DL, Thio CL, Martin MP, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
33. Rauch A, Kutalik Z, Descombes P, et al,. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345, 1345 e1331-1337.
34. Lange CM, Zeuzem S,. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 2011; 55: 692-701.
35. McCarthy JJ, Li JH, Thompson A, et al,. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-2314.
36. Kawaoka T, Hayes CN, Ohishi W, et al,. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol 2011; 54: 408-414.
37. Moghaddam A, Melum E, Reinton N, et al,. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-754.
38. Scherzer TM, Hofer H, Staettermayer AF, et al,. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 2011; 54: 866-871.
39. Mangia A, Thompson AJ, Santoro R, et al,. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827, 827 e821.
40. Rallon NI, Restrepo C, Naggie S, et al,. Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. AIDS 2011; 25: 269-271.
41. Fukuhara T, Taketomi A, Motomura T, et al,. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585, 1585 e1571-1573.
42. Lange CM, Moradpour D, Doehring A, et al,. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011; 55: 322-327.
43. Charlton MR, Thompson A, Veldt BJ, et al,. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-324.
44. Carbonari M, Caprini E, Tedesco T, et al,. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol 2005; 174: 6532-6539.
45. Newkirk MM,. Rheumatoid factors: host resistance or autoimmunity? Clin Immunol (Orlando, Fla) 2002; 104: 1-13.
46. Nowak UM, Newkirk MM,. Rheumatoid factors: good or bad for you? Int Arch Allergy Immunol 2005; 138: 180-188.
47. Feldmann G, Nischalke HD, Nattermann J, et al,. Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 4491-4498.
48. Nischalke HD, Coenen M, Berger C, et al,. The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer 2011; 130 (6): 1470-1475.
49. Dolganiuc A, Oak S, Kodys K, et al,. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004; 127: 1513-1524.
50. Gragnani L, Piluso A, Giannini C, et al,. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcgamma receptors. Arthritis Rheum 2011; 63: 1446-1451.
51. Ferri C, Sebastiani M, Giuggioli D, et al,. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33: 355-374.
52. Petrarca A, Rigacci L, Caini P, et al,. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010; 116: 335-342.
53. Strader DB, Wright T, Thomas DL, et al,. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.
54. Gaiani S, Gramantieri L, Venturoli N, et al,. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol 1997; 27: 979-985.
55. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
56. Zaja F, De Vita S, Mazzaro C, et al,. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-3834.
57. Zignego AL, Ferri C, Giannelli F, et al,. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002; 137: 571-580.
58. McHutchison JG,. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care. Liver Int 2011; 31 (Suppl 1): 29-35.
59. Afdhal NH, McHutchison JG, Zeuzem S, et al,. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011; 53: 336-345.
60. Pozzato G, Burrone O, Baba K, et al,. Ethnic difference in the prevalence of monoclonal B-cell proliferation in patients affected by hepatitis C virus chronic liver disease. J Hepatol 1999; 30: 990-994.
61. Antonelli A, Ferri C, Ferrari SM, et al,. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab 2009; 5: 26-34.
62. Antonelli A, Ferri C, Galeazzi M, et al,. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol 2008; 26: S39-47.
63. Antonelli A, Ferri C, Fallahi P, et al,. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. QJM 2004; 97: 499-506.
64. Antonelli A, Ferri C, Ferrari SM, et al,. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev 2008; 8: 18-23.
65. Sarrazin C, Susser S, Doehring A, et al,. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-421.
66. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
67. Hadziyannis SJ, Sette H Jr, Morgan TR, et al,. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.